header logo image


Page 29«..1020..28293031..40..»

Archive for the ‘Personalized Medicine’ Category

Genedata and the Crohn’s & Colitis Foundation Collaborate to Improve Patient Care in Crohn’s Disease – PR Web

Thursday, January 30th, 2020

This collaboration is helping us accelerate our search for precision biomarkers to prognosticate disease course and to guide early and effective personalized treatment decisions in Crohns disease patients.

BASEL, Switzerland (PRWEB) January 30, 2020

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful completion of a Data Science Services project in support of the Crohns & Colitis Foundations mission to advance precision medicines for Crohns disease and to improve patients quality of life. Researchers and clinicians collaborated with Genedata data scientists to integrate and analyze multi-omic and clinical data collected from large cohorts of patients with Crohns disease, to identify the most informative biomarkers that can be used to assess the risk to develop serious complications requiring surgery within five years after diagnosis. The combination of certain clinical parameters and specific omic biomarkers has the potential to lead to significant improvement in Crohns disease patient care.

The Crohns & Colitis Foundation, the leading non-profit organization focused on research and patient care in inflammatory bowel diseases (IBD) for over 50 years, serves as a hub for Crohns disease research with the largest collection of IBD patient data from institutions around the world. To achieve the goal of accelerating treatments and cures, the Crohns & Colitis Foundation looked for a partner to leverage the multitude of longitudinal clinical and molecular data from different omic technologies from large Crohns disease cohorts. In choosing Genedata as its partner to integrate and analyze their vast collection of clinical and high-dimensional molecular data, the Crohns & Colitis Foundation recognized the firms extensive domain expertise gleaned over more than 20 years, along with the benefits offered by its unique precision medicine software platform for translational and clinical research, Genedata Profiler. The Genedata team of expert bioinformaticians leveraged these resources to deliver actionable results that could be used to develop a diagnostic product.

Crohns disease is a chronic, often debilitating disease, for which there is currently no cure. Despite several treatment options, currently we lack predictive tests to determine the optimal treatment strategy early in the disease process, when the opportunity to improve outcomes is greatest. There is a significant unmet need to advance new diagnostic tools to enable precision medicine approaches and to optimize patient care according to the severity of the disease course, said Andrs Hurtado-Lorenzo, Ph.D., Senior Director of Translational Research at the Crohns & Colitis Foundation. We decided to implement cutting-edge data analysis methods to integrate clinical and genomic data from patients, as a strategy to advance our biomarker research efforts. We are pleased to have found in Genedata a trusted and reliable partner who provided us with expert knowledge in big multi-omic data analysis. This collaboration is helping us accelerate our search for precision biomarkers to prognosticate disease course and to guide early and effective personalized treatment decisions in Crohns disease patients.

Commenting on the successful completion of the recent project, the CEO of Genedata, Othmar Pfannes, Ph.D., said, The volume and complexity of multi-omic data together with clinical data is growingly rapidly and is challenging to analyze. Our Data Science Services together with our Genedata Profiler platform is set up to address this challenge and to enable our partners to make data-informed decisions on a per-project basis without having to build their own data infrastructure or hire data scientists. Dr. Pfannes continued, We are proud that our expertise has been helpful to the Crohns & Colitis Foundation.

About the Crohns & Colitis FoundationThe Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel diseases (IBD). The Foundations mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life for the more than 3 million Americans living with IBD. Its work is dramatically accelerating the research process through its database and investment initiatives; the Foundation also provides extensive educational resources for patients and their families, medical professionals, and the public. For more information, visit http://www.crohnscolitisfoundation.org, call +1-888-694-8872, or email info@crohnscolitisfoundation.org.

About GenedataGenedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US. http://www.genedata.comLinkedIn | Twitter | YouTube

ContactMiles Fisher-PollardGenedataPublic RelationsPhone: +41 61 511 85 61pr@genedata.com

DisclaimerThe statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:

See original here:
Genedata and the Crohn's & Colitis Foundation Collaborate to Improve Patient Care in Crohn's Disease - PR Web

Read More...

Intermountain Precision Genomics Announces Advancements in Personalized Cancer Care with Expanded TheraMap Test – Press Release – Digital Journal

Thursday, January 30th, 2020

This press release was orginally distributed by ReleaseWire

Salt Lake City, UT -- (ReleaseWire) -- 01/29/2020 -- Intermountain Precision Genomics continues to expand cancer testing through advancements to TheraMap, a test for advanced-stage cancer patients. The new TheraMap test expands the ability to examine a tumor's DNA to provide individualized treatment options.

Cancer is caused by changes in DNA that can make a normal cell become cancerous. Utilizing state-of-the-art genomic technology, TheraMap analyzes and interprets what changes, or gene mutations are present in a patient's tumor DNA.

With the ability to detect important mutation types across more than 500 genes relevant to cancer treatment, relevant gene fusion events including NTRK fusions, and important microsatellite instability (MSI) and tumor mutational burden (TMB) biomarkers, TheraMap results can be used to personalize treatment for each patient.

In addition to its significant gene panel, another feature that sets TheraMap aside from other cancer tests is the molecular tumor board, a multi-institutional group of clinical experts and precision medicine leaders who review the solid tumor results and provide oncologists with recommendations for specific therapies and treatments.

"Our unique process analyzes the genetic makeup of a patient's cancer and employs a team of skilled Molecular Tumor Specialists to review each solid tumor test and determine how to most effectively treat that cancer case," said Lincoln Nadauld, MD, PhD, oncologist and chief of Precision Health and Genomics at Intermountain Healthcare. "Our team approach gives oncologists confidence, information, and support they need to prepare a customized, targeted treatment plan for each patient."

When compared to traditional diagnostic tests and treatment, TheraMap's methods provide significantly better results for patients at lower overall healthcare costs something patient Jeffery Layne appreciates.

In January 2018, Layne was diagnosed with stage four kidney cancer that had spread to other parts of his body and was told that he would have six months to two years to live. Layne's oncologist, Derrick Haslem, MD, associate medical director for the Intermountain Healthcare Oncology Clinical Program, recommended that he try TheraMap.

"The TheraMap test helped to determine exactly what gene mutations were causing Mr. Layne's cancer, allowing us to create an individualized plan for him," said Dr. Haslem.

Utilizing TheraMap's results, Dr. Haslem discovered Layne would be a good candidate for immunotherapy treatment, a personalized infusion that boosts the body's own immune system to fight cancer.

Layne showed a quick response to the treatment with masses under his arms shrinking almost immediately. After just two months of immunotherapy, the masses disappeared and tumors on his lungs were significantly smaller.

"They've come so far in being able to diagnose the problems related to cancer, it's just amazing," said Layne. "As a cancer patient, watching all the progress in precision medicine and cancer research is really encouraging."

Two years later, Layne continues to improve while painting and spending time with his grandkids. View more about Jeffrey Layne's story.

"Intermountain Precision Genomics is pleased with the advances in TheraMap that will continue to help our advanced-cancer patients see better results, which are longer lives and overall improved quality of life," said Dr. Nadauld.

Visit intermountainhealthcare.org/abouttheramap for more information about TheraMap testing.

About Intermountain Precision GenomicsIntermountain Precision Genomics is transforming healthcare by targeting treatment to deliver the highest quality care at some of the lowest costs in the nation, all while helping people live the healthiest lives possible. Intermountain Precision Genomics is a service of Intermountain Healthcare, a system widely recognized as a leader in clinical quality improvement and efficient healthcare delivery. For more information about Intermountain Precision Genomics, please visit intermountainhealthcare.org/genomics.

For more information on this press release visit: http://www.releasewire.com/press-releases/intermountain-precision-genomics-announces-advancements-in-personalized-cancer-care-with-expanded-theramap-test-1273295.htm

Link:
Intermountain Precision Genomics Announces Advancements in Personalized Cancer Care with Expanded TheraMap Test - Press Release - Digital Journal

Read More...

Precision Health Informatics and Concerto HealthAI to Collaborate on Advanced Precision Medicine Solutions – Yahoo Finance

Monday, January 20th, 2020

Concerto HealthAI's Real-World Data analytical capabilities will enable Precision Health Informatics to accelerate innovation in cancer testing and treatment

DALLAS and BOSTON, Jan. 14, 2020 /PRNewswire-PRWeb/ --Concerto HealthAI, the market leader for Real-World Data (RWD) and enterprise AI technology, announced today an agreement with Precision Health Informatics, a subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine to treat cancer patients. Precision Health Informatics will work with Concerto HealthAI to advance RWD solutions, research studies, and AI-enabled technologies focusing on genomic and molecular characterization of patient disease to develop effective new therapies to treat some of the most challenging and devastating cancers.

Precision Health Informatics will leverage Concerto HealthAI's eurekaHealth 3.0 enterprise AI solution to advance precision medicine solutions for clinical research. Using AI models to enrich clinical data, Precision Health Informatics will more quickly derive insights from patient data to inform new study designs or identify eligible patients for clinical studies. Precision Health Informatics joins an expanding set of Concerto HealthAI's Real-World Evidence collaborators, such as theAmerican Society of Clinical Oncology's CancerLinQ relationship announced in late 2017.

"Precision Health Informatics' model uses information from the molecular profile representing the genetics of the patient's disease combined with the clinical information specific to that patient to develop personalized medicine solutions that are integral to diagnosing cancer and offering physicians and patients effective treatment options," said Lori Brisbin, Vice President for Precision Health Informatics, "Concerto HealthAI's leadership in solutions for precision medicine will help us derive more meaningful insights from patient data, that in turn may help us connect patients with appropriate clinical trials."

"Using data from Texas Oncology's large patient base, Precision Health Informatics is at the forefront of precision medicine, innovative cancer testing and diagnostic approaches, such as Next Generation Sequencing changing and improving the standard of care for patients. Ultimately, this is all about developing and connecting cancer patients to precise, effective treatment," said R. Steven Paulson, MD, President of Precision Health Informatics, and President and Chairman of Texas Oncology. "Concerto HealthAI's deep expertise in research-grade RWD solutions and AI technologies make it the ideal collaborator with Precision Health Informatics to help us more quickly develop medical innovations that benefit patients in our practice and elsewhere."

"At Concerto HealthAI, we seek clinical collaborators committed to advancing insights and new treatment strategies for patients with the highest unmet medical needs," said Jeff Elton, PhD, CEO of Concerto HealthAI. "Precision Health Informatics is making a deep commitment to enabling precision medicine, which we see as highly complementary to the work of our biomedical innovator partners."

This collaboration will advance novel research solutions, integrating deep clinical insights derived from electronic medical record data, particularly information about the molecular basis of disease derived from tissue or liquid samples. The value of these insights in helping connect patients to effective treatment options will be made available to Texas Oncology patients through its precision medicine program.

About Concerto HealthAI Concerto HealthAI is a technology leader in Definitive Real-World Data (RWD) and AI solutions for Precision Oncology. Our mission is to bring together unique data assets, leading AI-based technologies, and the world's top outcomes research and data science talent. Our focus is on revolutionizing clinical and outcomes research to accelerate the insights benefitting patient treatment. For more information, visit us at http://www.concertohealthai.com.

About Precision Health Informatics and Texas Oncology Precision Health Informatics, a subsidiary of Texas Oncology, is a precision medicine solutions company that uses patients' genetic information for innovative testing, diagnostics, and treatment of cancer. Precision Health Informatics' solutions are based on data-driven insights from a vast, diverse patient base. Texas Oncology is an independent private practice with more than 460 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 90 FDA-approved therapies, about one-third of all cancer therapies approved to date. For more information, visit http://www.texasoncology.com.

MEDIA CONTACTS

Jen Toole Concerto HealthAI 617.779.1828 jtoole@shiftcomm.com

Ed Bryson Texas Oncology 512.592.8190 edward.bryson@usoncology.com

SOURCE Concerto HealthAI

More here:
Precision Health Informatics and Concerto HealthAI to Collaborate on Advanced Precision Medicine Solutions - Yahoo Finance

Read More...

Moderna Partners with AWS to Explore the ‘Software of Life’ – BioSpace

Monday, January 20th, 2020

The software of life. Thats how Stephane Bancel, the chief executive officer of Moderna, described messenger RNA (mRNA), which is at the core of Modernas drug development process.

Moderna is pioneering mRNA drugs that are believed to be able to direct the body to produce any protein of interest, including antibodies and other proteins that can create therapeutic activity. Bancel said mRNA is an information molecule.

Its like software, he said.

The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer. In order to create those personalized medicines, the Cambridge, Mass.-based company relies on gene sequencing and a partnership with one of the worlds largest companies Amazon.

In an interview with CNBCs Jim Cramer during the J.P. Morgan Healthcare Conference this week, Bancel said the company relies on Amazon Web Services to compare every letter of DNA in the sequencing process. Once that is done, the company can deduce what needs to be done to develop personalized medicine, Bancel explained.

Amazon Web Services, the fastest growing division of the company, according to CNBC, provides on-demand cloud computing platforms to companies. Moderna is currently using Amazon Web Services with more than a dozen drug candidates in its pipeline, which means the high-tech platform plays a central role in the companys drug development program. As CNBC explains, the company is using the powerful cloud-based service to speed up the time it takes a drug candidate to move from the preclinical to the clinical phase. In addition to Moderna, Amazon Web Services is being used by several pharmaceutical companies, including San Diego-based Human Longevity Inc., Regeneron Pharmaceuticals and more.

The reliance on the high-speed program could lead to the company finally becoming a commercial entity 10 years after it was launched. Last week, just ahead of JPM, Bancel pointed to one of the companys clinical candidates as a potential blockbuster, an experimental treatment for cytomegalovirus (CMV), the most common infectious cause of birth defects in the United States.

Moderna said the analysis following a Phase I trial, which was taken after the third and final vaccination, shows continued boosting of neutralizing antibody titers in patients. The mRNA-based vaccine, mRNA-1647, is designed to protect against CMV infection. Cytomegalovirus is a common pathogen and is the leading infectious cause of birth defects in the United States with approximately 25,000 newborns in the U.S. infected every year. CMV is passed from the mother to her unborn child. Birth defects occur in about 20% of infected babies. The defects can include neurodevelopmental disabilities such as hearing loss, vision impairment, varying degrees of learning disability and decreased muscle strength and coordination. There is no approved vaccine to prevent CMV infection.

In October, the company received Fast Track Designation from the U.S. Food and Drug Administration for mRNA-3927, its investigational mRNA therapeutic for propionic academia, which is caused by the inability of the body to breakdown certain proteins and fats which leads to the build-up of toxic chemicals. Moderna plans to initiate an open-label, multi-center, dose-escalation Phase I/II study of multiple ascending doses of mRNA-3927 in primarily pediatric patients.

Read the original:
Moderna Partners with AWS to Explore the 'Software of Life' - BioSpace

Read More...

Is Cloud Computing the Answer to Genomics Big Data… – Labiotech.eu

Monday, January 20th, 2020

The success of the genomics industry has led to generation of huge amounts of sequence data. If put to good use, this information has the potential to revolutionize medicine, but the expense of the high-powered computers needed to achieve this is making full exploitation of the data difficult. Could cloud computing be the answer?

Over the last decade, genomics has become the backbone of drug discovery. It has allowed scientists to develop more targeted therapies, boosting the chances of successful clinical trials. In 2018 alone, over 40% of FDA-approved drugs had the capacity for being personalized to patients, largely based on genomics data. As the percentage has doubled over the past four years, this trend is unlikely to slow down anytime soon.

The ever-increasing use of genomics in the realm of drug discovery and personalized treatments can be traced back to two significant developments over the past decade: plunging sequencing costs and, consequently, an explosion of data.

As sequencing technologies are constantly evolving and being optimized, the cost of sequencing a genome has plummeted. The first sequenced genome, part of the Human Genome Project, cost 2.4B and took around 13 years to complete. Fast forward to today, and you can get your genome sequenced in less than a day for under 900.

According to the Global Alliance for Genomics and Health, more than 100 million genomes will have been sequenced in a healthcare setting by 2025. Most of these genomes will be sequenced as part of large-scale genomic projects stemming from both big pharma and national population genomics initiatives. These efforts are already garnering immense quantities of data that are only likely to increase over time. With the right analysis and interpretation, this information could push precision medicine into a new golden age.

Are we ready to deal with enormous quantities of data?

Genomics is now considered a legitimate big data field just one whole human genome sequence produces approximately 200 gigabytes of raw data. If we manage to sequence 100M genomes by 2025 we will have accumulated over 20B gigabytes of raw data. The massive amount of data can partially be managed through data compression technologies, with companies such as Petagene, but that doesnt solve the whole problem.

Whats more, sequencing is futile unless each genome is thoroughly analyzed to achieve meaningful scientific insights. Genomics data analysis normally generates an additional 100 gigabytes of data per genome for downstream analysis, and requires massive computing power supported by large computer clusters a feat that is economically unfeasible for the majority of companies and institutions.

Researchers working with large genomics datasets have been searching for other solutions, because relying solely on such high-performance computers (HPC) for data analysis is economically out of the question for many. Large servers require exorbitant amounts of capital upfront and incur significant maintenance overheads. Not to mention, specialized and high-level hardware, such as graphics processing units, require constant upgrades to remain performant.

Furthermore, as most HPCs have different configurations, ranging from technical specs to required software, the reproducibility of genomics analyses across different infrastructures is not a trivial feat.

Cloud computing: a data solution for small companies

Cloud computing has emerged as a viable way to analyze large datasets fast without having to worry about maintaining and upgrading servers. Simply put, Cloud computing is a pay-as-you-go model allowing you to rent computational power and storage. and its pervasive across many different sectors.

According to Univa the industrial leader in workload scheduling in the cloud and HPC more than 90% of organizations requiring high performance computing capacity have moved, or are looking into moving to the cloud. Although this is not specific for companies in the life sciences, Gary Tyreman Univas CEO suggests that pharmaceutical companies are ahead of the market in terms of adoption.

The cloud offers flexibility, an alluring characteristic for small life science companies that may not have the capital on-hand to commit to large upfront expenses for IT infrastructure: HPC costs can make or break any company. As a consequence, many opt to test their product in the cloud first, and if numbers look profitable, they can then invest in an in-house HPC solution.

The inherent elasticity of cloud resources enables companies to scale their computational resources in relation to the amount of genomic data that they need to analyze. Unlike with in-house HPCs, this means that there is no risk money will be wasted on idle computational resources.

Elasticity also extends to storage: data can be downloaded directly to the cloud and removed once the analyses are finished, with many protocols and best practices in place to ensure data protection. Cloud resources are allocated in virtualized slices called instances. Each instance hardware and software is pre-configured according to the users demand, ensuring reproducibility.

Will Jones, CTO of Sano Genetics, a startup based in Cambridge, UK, offering consumer genetic tests with support for study recruitment, believes the cloud is the future of drug discovery. The company carries out large data analyses for researchers using its services in the cloud.

In a partnership between Sano Genetics and another Cambridge-based biotech, Joness team used the cloud to complete the study at a tenth of the cost and in a fraction of the time it would have taken with alternative solutions.

Besides economic efficiency, Jones says that moving operations to the cloud has provided Sano Genetics with an additional security layer, as the leading cloud providers have developed best practices and tools to ensure data protection.

Why isnt cloud computing more mainstream in genomics?

Despite all of the positives of cloud computing, we havent seen a global adoption of the cloud in the genomics sector yet.

Medley Genomics a US-based startup using genomics to improve diagnosis and treatment of complex heterogeneous diseases, such as cancer moved all company operations to the cloud in 2019 in a partnership with London-based Lifebit.

Having spent more than 25 years at the interface between genomics and medicine, Patrice Milos, CEO and co-founder of Medley Genomics, recognized that cloud uptake has been slow in the field of drug discovery, as the cloud has several limitations that are preventing its widespread adoption.

For starters, long-term cloud storage is more expensive than the HPC counterpart: cloud solutions charge per month per gigabyte, whereas with HPC, once youve upgraded your storage disk, you have no additional costs. The same goes for computing costs: while the cloud offers elasticity, Univas CEO Tyreman says that the computation cost of a single analysis is five times more expensive compared to an HPC solution in many scenarios. However, as cloud technologies continue to progress and the market becomes increasingly more competitive among providers, the ongoing cloud war will likely bring prices down.

Furthermore, in the world of drug discovery, privacy and data safety are paramount. While cloud providers have developed protocols to ensure the data is safe, some risks still exist, for example, when moving the data. Therefore, large pharmaceutical companies prefer internal solutions to minimize these risks.

According to Milos, privacy remains the main obstacle for pharmaceutical companies to fully embrace the cloud, while the cost to move operations away from HPCs is no longer a barrier. While risks will always exist to a certain extent, Milos highlighted that the cloud allows seamless collaboration and reproducibility, both of which are essential for research and drug discovery.

Current players in the cloud genomics space

Cloud computing is a booming business and 86% of cloud customers rely on three main providers: AWS (Amazon), Azure (Microsoft) and Google Cloud. Although the three giants currently control the market, many other providers exist, offering more specialized commercial and academic services.

Emerging companies are now leveraging the technology offered by cloud providers to offer bioinformatics solutions in the cloud, such as London-based Lifebit, whose technology allows users to run any bioinformatics analyses through any cloud provider with a user-friendly interface effectively democratizing bioinformatics for all researchers, regardless of skill set.

Federation is a concept from computing now used in the field of genomics. It allows separate computers in different networks to work together to perform secure analysis without having to expose private data to others, effectively removing any potential security issues.

The amount of data organizations are now dealing with has become absolutely unmanageable with traditional technologies, and is too big to even think about moving, explained Maria Chatzou Dunford, Lifebits CEO and co-founder.

When data is moved, you increase the chances of having it be intercepted by third-parties, essentially putting it at significant risk. Data federation is the only way around this unnecessary data storage and duplication costs, and painstakingly slow data transfers become a thing of the past.

Getting ready for the genomics revolution

Its no secret that genomics is key to enabling personalized medicine and advancing drug discovery. We are now seeing a genomics revolution where we have an unprecedented amount of data ready to be analyzed.

The challenge now is: are we ready for it? To be analyzed, big data requires massive computation power, effectively becoming an entry barrier for most small organizations. Cloud computing provides an alternative to scale analyses, while at the same time, facilitating reproducibility and collaboration

While the cost and security limitations of cloud computing are preventing companies from fully embracing the cloud, these drawbacks are technical and are expected to be resolved within the next few years.

Many believe that the benefits of the cloud heavily outweigh its limitations. With major tech giants competing to offer the best cloud solutions a market valued at $340 billion by 2024 we might be able to expect a drastic reduction in costs. While some privacy concerns may still exist, leading genomics organizations are developing new tools and technologies to protect genomic data.

Taken as a whole, it is likely that the cloud will be increasingly important in accelerating drug discovery and personalized medicine. According to Univas Tyreman, it will take around 1015 years to see the accelerated transition from HPC to cloud, as large organizations are often conservative in embracing novel approaches.

Distributed big data is the number one overwhelming challenge for life sciences today, the major obstacle impeding progress for precision medicine, Chatzou Dunford concluded.

The cloud and associated technologies are already powering intelligent data-driven insights, accelerating research, discovery and novel therapies. I have no doubt we are on the cusp of a genomics revolution.

Filippo Abbondanza is a PhD candidate in Human Genomics at the University of St Andrews in the UK. While doing his PhD, he is doing an internship at Lifebit and is working as marketing assistant at Global Biotech Revolution, a not-for-profit company growing the next generation of biotech leaders. When not working, he posts news on LinkedIn and Twitter.

Images via E. Resko, Lifebit and Shutterstock

See the article here:
Is Cloud Computing the Answer to Genomics Big Data... - Labiotech.eu

Read More...

Leadership in the Age of Personalization is About Creating Healthy Environments So People Can Thrive – Forbes

Monday, January 20th, 2020

This is Part 8 of an eight-part series featuring thought-provoking insights from theLeadership in the Age of Personalization Summit. Here is Part 1, Part 2, Part 3, Part 4, Part 5, Part 6 and Part 7.

All Employers are in the Business of Health

My definition of harmony is when your head, your heart, your feet, and your gut are all going in the same direction.

I love that quote. In the context of business, we could think of the head as your strategy, the heart as your vision, the feet as your operating model and forgive the metaphor the gut as your source of fuel. Its where your resources churn and create the energy that makes everything else possible.

In other words, its your people.

Are your head, heart, feet and gut in harmony? Or, more likely, is your gut a little upset? Off balance? Irritated?

Think about how difficult it is to get anything done when your actual, physical gut is irritated. A large organization is the same. You can have a bold vision, a smart strategy, an effective operating model. But if your people are feeling stifled, not activated to their fullest potential, or bogged down by physical, emotional or financial health issues, none of that other stuff will make a difference.

In my last article, part 7 of this series, we heard from healthcare leaders. But the reality is were all in the business of health. No matter your industry, the physical, mental and financial health of your employees and their families affects your bottom line and your ability to thrive as an organization. The health of your customers and the communities you serve also affect the scope of the impact you can have.

How does this fit into this series of articles on our societys transition from an age of standardization to our current age of personalization? Heres a story that might help connect the dots.

A few years ago I met with some C-level executives at a company. I made a bold prediction: You probably have someone at the executive level who has a chronic disease or cares for someone with a chronic disease that is not covered by your insurance. They're probably struggling to get by, even with an executive salary."

Most respectfully disagreed with my prediction. But one person at the table scribbled a note and the CEO said: "Looks like I'm wrong." There was a VP who was living out of his car because he was paying for his mother's cancer and a grandparents diabetes.

If were leading in a way that honors this age of personalization, everything about that scenario should change. Ill leave it to the experts to fix our system so caring for sick family members wont cost so much. But we can at least we can create workplace cultures that dont make someone feel like they must hide such hardships from their peers.

We need systems in place for getting to know people as individuals. People shouldnt be afraid to discuss health issues related to physical or mental health. If they are afraid, youve got a problem.

In its Mental Health at Work 2019 Report, Mind Share Partners shares results from surveying 1,500 people in the United States: nearly 60% of respondentsreported symptoms of a mental health condition in the past year; and almost 60% of people never talked to anyone at work about their mental health in the last year. No wonder: when conversations about mental health did occur, less than half were described as a positive experience. One result? Youll lose good people. According to the survey, 50% of millennials, 75% of Gen Z-ers and 34% overall had left roles for mental health reasons, both voluntarily and involuntarily.

How do we as leaders open ourselves up so that people will be comfortable to be in their most vulnerable state?

This subject was tackled at the Leadership in the Age of Personalization Summit, where senior leaders from industries spanning healthcare, automotive, finance, consumer packaged goods, retail, technology, apparel and more, gathered to explore the tension were all feeling in this shift from standardization to personalization.

Throughout the day we discussed building economies of scale around human dignity, how to escape the extremes to achieve balance, how assimilation destroys individuality and inclusion restores it, how to allow personalized values to influence your brand identity, Wall Streets perspective on how companies are not prepared for what is about to hit them, how a companys mission is worthless without individual contribution and the importance of what you measure.

Tending to Employees Mental Health

Stephanie Neuvirth is the Senior Vice President of People and Organization at Banfield Pet Hospital.

She said Banfields people strategy is its business strategy, because to keep growing as a company they need to attract and retain more healthcare professionals a goal made more challenging by the cost of veterinary school and high levels of compassion fatigue among practitioners.

The pet space is growing at double digit growth, she said. As we look at the growth of our business and the trajectory over the next 10 years, and then look at the supply of the individuals in our space, candidly, the biggest concern to our growth strategy is our ability to find and keep great talent.

Stephanie Neuvirth and Gyasi Chisley during their panel discussion at the Leadership in the Age of ... [+] Personalization Executive Summit.

Banfield leaders believe theres a connection between Banfields commitment to preventive health for pets and its commitment to the health and energy of employees (whom they call associates). They deal with many of the same challenges as people in human healthcare do.

We see very high levels of compassion fatigue, high levels of suicide, high levels of burnout, said Neuvirth. What we see is a very serious and concerning situation about the profile of the individuals that go into our profession. They tend to be perfectionists. They are burdened with tremendous student debt. All of these things combined make it a very, very challenging environment.

Banfields health & wellbeing approach encompasses five areas: body, mind, finances, career and community.

We believe that all five parts are very important, and it's a different combination for every single person, said Neuvirth. For some, their biggest stressor is financial. For others its about not feeling connected to community. For others, it really is about not getting the career growth that they're looking for. So we're focused on how we bring all five parts to life and how to solve for the various combinations.

Ive written in the past about Banfields Veterinary Student Debt Relief Program (read about it here): Managing Employee Stress, Debt, and Emotional Turmoil in the Age of Personalization.

The nations largest general veterinary practice is also putting particular attention and resources behind mental health, addressing the suicide epidemic head-on.

According to the CDC, one in six veterinarians has considered suicide, said Neuvirth. Those are staggering and very concerning numbers. In 2018, we hired a mental health professional and are looking at partnering with social workers, not just for our client experience but for our associates.

She said they recently rolled out a first-of-its kind suicide prevention training for veterinary professionals called ASK Assess, Support, Know.

ASK is intended not only to support our own associates, but also to give them tools to spot emotional distress and suicidal thoughts in their colleagues, she said. In addition to making the ASK e-learning available to all 19,000+ Banfield associates nationwide, we also closed schedules at all of our 1,000+ Banfield hospitals for two hours to offer an interactive mental health and wellbeing training.

And theyre sharing the ASK training and resources with the industry.

As one of the largest employers in the veterinary health space, we feel a responsibility to support the entire profession, said Neuvirth. In observance of the harrowing 1-in-6 statistic, we made ASK available to the entire profession, including U.S. vet schools, on January 6, 2020.

That last part is so important: finding creative solutions and then sharing them with others.

In past articles Ive talked about discovering what you solve for as an individual what you solve for is what you consistently think about in a big way, the problems you are typically drawn to, and the kinds of solutions you favor. But it also applies to organizations.

One of the things Banfield is solving for is suicide awareness and prevention among healthcare professionals, and theyve created a method that can be used by others facing similar challenges. This is what can happen when you start tending to your gut and put individuals at the center of your strategy.

Making Cancer Care More Precise

Going back to healthcare in particular, one of our biggest challenges is to make sure our increasing levels of personalized care are accessible to all people. Next Ill share the personalization of cancer care from the viewpoint of a physician providing the care and then an executive of an organization expanding access to care.

Dr. Joseph Alvarnas is Vice President of Government Affairs, Senior Medical Director for Employer Strategy, and Associate Clinical Professor in the Department of Hematology/Hematopoietic Cell Transplantation at City of Hope.

He described how this tension between personalization and standardization has actually changed paradigms of care.

I'm a cancer care provider, he said. We've entered an era of precision medicine. So, things that we would have thought about as one cancer a decade ago when you look at them very closely on a genetic level, you realize they represent hundreds of different of sub-types of cancer.

He said there are about 22,300 genes in the human genome.

That's the entire instruction set to make, maintain, sustain a human being over the course of our lives, he said. Sometimes those genes go wrong in very, very particular ways. We're learning about these things at a pace that I would never have imagined years ago, and we're seeing innovations directed at very specific genetic mutations in cancer.

Dr. Alvarnas speaks at the Leadership in the Age of Personalization Executive Summit.

This idea that we can understand the genetic nature of someone's cancer, identify the exact correct therapeutic, and bring it to that individual in a timely, efficient, rapid way, said Dr. Alvarnas, so that we don't give wrong care, we mitigate unnecessary toxicities, we get that person well, keep them home, get them back to life that's actually real. That's the precision and personalized medicine paradigm for delivering care.

Talk about personalization. But he also posed this challenge: How do you create a system of high through-put knowledge understanding, and then marshal it to the needs of a patient in a family in a highly personalized way?

Because cancer care is not a technological experience, it's a human experience, said Dr. Alvarnas. We don't treat diseases. We care for patients and their families, because families are as responsible for good outcomes as any of the most critical elements of what we do.

Then he made the connection to employers.

Employers are invested in this, because not only do employers bear the costs for misadventures in care, but they also bear witness to the human consequences of what it's like to have an employee or a family member, or someone who's aligned with your company, go through a cancer journey.

Making Cancer Care More Accessible

Just as each cancer is different, so is each persons cancer journey.

Gyasi Chisley is another healthcare executive working hard to make those journeys as personalized as possible. He is President of Hospitals and Clinics for Cancer Treatment Centers of America (CTCA), a national comprehensive cancer care network with five hospitals around the country and a growing footprint of Outpatient Care Centers and other locations.

CTCA has been around for about 32 years, and its founder Richard J. Stephenson had the notion of creating a patient empowerment platform. Chisley said 82% of their patients live below the Federal Poverty Line. He said consumers come directly to them, usually for a second opinion, which means theyre often out-of-network.

A lot of the folks that were suffering from cancer or had that evil diagnosis were, number one, scared, and then number two, didn't have an opportunity to get that second opinion, said Chisley. So we started expanding through a footprint of what we call OIS, which is Oncology Information Systems just to get information out there directly to the patient. And that's been happening for 32 years.

They also took a holistic approach.

Our chairman had the foresight to say let's treat the patient holistically, with things like massage and acupuncture almost regardless of cost because we think thats better in the long run, said Chisley. But even more, what are the patient's goals? What are they really trying to achieve?

Chisley said one of the things theyre working on is going direct to employer, and having those crucial conversations with employers that will help them look at their workforce planning and look for opportunities for interventions that will ensure that the continuum of care is top of mind.

Glenn Llopis and Gyasi Chisley during their fireside chat at the Age of Personalization Executive ... [+] Summit.

We're not the most popular people in the payer's eyes these days we're doing things like having diet consults, we're doing things that are out of the box, if you will, for new cutting-edge clinical trials, and not always getting reimbursed from the payer, said Chisley. But you know what that is demonstrating? It's demonstrating to the employer that we're taking care of their people, and that's why we're going direct to employer and direct to consumer. So, that's opportunity for us, not only to be evolutionary, but revolutionary.

Chisley said after a day of hearing executives talk about personalization at the summit, hes inspired to dig even deeper as a leader: We see our patients come in at their most vulnerable times, particularly with this despicable disease of cancer. I've been vulnerable, but I haven't been vulnerable enough. And that's opportunity for me to be humble and make sure we're meeting our patients where they are.

An Appeal From Gen Z

Meeting people where they are. Thats what this age of personalization is all about.

After a full day of C-level leaders sharing their experiences and being vulnerable with each other, we closed the summit with a different kind of VIP your current customer, your future employee and, frankly, your future leader.

Brielle Lubin is in 8th grade. She describes herself as born from a Jewish-American father and a Japanese mother from Tokyo. She is very proud of her Jewish-American culture and is equally proud of her Japanese culture. At her school in Los Angeles she leads two clubs: the Gender Sexuality Awareness Club and the Asian American Cultural Club.

Throughout the day of the summit, she had been playing piano in the background. When she addressed the audience from the stage at the end of the day, she did it with the confidence of someone who already gives thought and action to these ideas of personalization.

Heres just a sampling of what she shared with us:

As a part of the youth community, we're always told, You have no idea what you're talking about. That's so ridiculous. That's frivolous. You're too young.

I may not be the CEO of a company like everyone else here. I'm just some 14-year-old kid. But you know what? When we're told when we're younger, Hey, you can be yourself, you can express your opinion, there are places where people can talk to you and help you I find that to be the most important thing. Because we cannot start assimilating when were young, if [our goal is to] avoid assimilating when we're older.

Brielle Lubin speaks at the Leadership in the Age of Personalization Executive Summit.

Everyone is a different shade of a color in the entire color spectrum. None of us is exactly the same. There's always some sort of shade that's just a little bit off, and that's the most important thing and we need to acknowledge that because identity crisis occurs the most when we don't recognize that difference, when we think we need to blend with other colors.

When people try to paint something, they don't just blend every single color of the rainbow together. They use all the colors individually, use them as a different shade on a different part of the paper, and that's what we are. We are all that different shade of a color on that paper.

Welcome to the Age of Personalization

Consider what Brielle said. This is the thinking thats already entering your workforce today, and will be in full force within your organizations in the next 10 years.

If youre not already trying to create the systems that allow for this level of inclusive leadership, you will not remain relevant in a marketplace where consumers and employees value their individuality.

The luxury of time is over, and I want to leave you with this sense of urgency. Throughout this series we have explored the difference between leadership in the age of standardization and in the age of personalization. But this is just the beginning.

Knowing something is right isnt enough to start doing it. And knowing something is wrong isnt enough to stop doing it.

We are a nation burning out at work not just because were working so hard and so much, but because were doing that without any sense of who we are and any connection to what we are doing. Engaged or not, the negative forces of standardization have stripped so many of us of our identities.

Only by rediscovering who we are as individuals and embracing that individuality in others can we find our purpose and contribute to a healthier whole.

Leadership in the age of personalization is about creating healthy environments we can all thrive in. It is the force that will push us to start over again. I see this as the beginning of a movement. And now the question is: what are you going to do about it?

Read more from the original source:
Leadership in the Age of Personalization is About Creating Healthy Environments So People Can Thrive - Forbes

Read More...

Scientists Discover 4 Distinct Patterns of Aging – Livescience.com

Monday, January 20th, 2020

Some people's hearts stay strong well into their 60s, but their kidneys begin to fail. Others may have the kidneys of a 30-year-old but fall victim to constant infection.

Now, scientists may be one step closer to understanding why the aging process varies so drastically between people.

Even within a single person, aging unfolds at different rates in different tissues, sometimes striking the liver before the heart or kidney, for example. People fall into distinct categories depending on which of their biological systems ages fastest, and someday, doctors could use this information to recommend specific lifestyle changes and design personalized medical treatments, according to a new study, published Jan. 13 in the journal Nature Medicine.

The research team behind the study sorted 43 people into aging categories, or "ageotypes," based on biological samples collected over the course of two years. The samples included blood, inflammatory substances, microbes, genetic material, proteins and by-products of metabolic processes. By tracking how the samples changed over time, the team identified about 600 so-called markers of aging values that predict the functional capacity of a tissue and essentially estimate its "biological age."

So far, the team has identified four distinct ageotypes: Immune, kidney, liver and metabolic. Some people fit squarely in one category, but others may meet the criteria for all four, depending on how their biological systems hold up with age.

"Now, it's going to be a lot more than just four categories," said senior author Michael Snyder, a professor and the chair of genetics at the Stanford University School of Medicine in California. For instance, one participant in the study appeared to be a cardiovascular ager, meaning their cardiac muscle accumulates wear-and-tear at a greater rate than other parts of their body. "If we [surveyed] 1,000 people, I'm sure we'll find other cardio agers and that category will become better defined." And with more research, even more patterns of aging may emerge, Snyder added.

Related: 8 Tips for Healthy Aging

In the past, scientists have hunted for markers of aging in enormous datasets for large populations, Snyder, told Live Science. Researchers pinpointed markers of aging by comparing data from young people to that of older people, but for individuals, that kind of data captures only a specific moment in time. It cannot reveal how a given person might change as they age, Snyder said.

In a clinical setting, that means population-based markers might not be the best measure to determine how a patient is aging, or what combination of medical treatments might suit them best, he added.

"Population-based decisions are crude at best," Synder said. They won't necessarily hold up for you, per se."

By tracking specific people through time, Snyder and his co-authors hoped to learn how aging markers differ between individuals. Their study participants ranged in age from 29 to 75 and provided at least five biological samples over the course of two years. Even within that relatively short time frame, several patterns of aging emerged.

For example, immunological agers accumulated more markers of inflammation through time, while metabolic agers accrued more sugar in their blood, indicating that their bodies were metabolizing glucose less efficiently. Similar to scores on a personality test, each individual's aging "profile" included a combination of traits, mixed and matched from different ageotypes.

Snyder and his co-authors plan to follow the study participants to see how their aging profiles morph over time. They also aim to develop a simple ageotype test that could be used in the doctor's office to quickly assess a patient's health status, and potentially point them toward the best possible treatment options.

"There are drugs and various kinds of dietary interventions and lifestyle interventions through which it may be possible to modulate some of these aging processes," Dr. James Kirkland, a gerontologist and head of the Kogod Center on Aging at the Mayo Clinic in Rochester, Minnesota, told NBC News.

"But in order to apply those correctly, we have to know which people to apply which drugs or which dietary interventions in order to get the most bang for the buck," said Kirkland, who was not involved in the new study.

Related: 7 Ways the Mind and Body Change With Age

While existing drugs, diets and exercise regimes can target some signs of aging, other markers aren't fully understood yet.

For example, over the course of Snyder's study, a marker of poor kidney function decreased in 12 individuals, eight of whom took statins. The marker, a waste product called creatinine, accumulates in the blood as muscle tissue naturally breaks down, but the kidneys typically filter the substance and expel it through the urine. Creatinine levels fell in the eight individuals on statins, suggesting that the medication improved their kidney function, though it's unclear why levels also dipped in four additional people, the authors noted.

The team also found that concentrations of several microbes seem to change with age, but we don't yet know how that may affect health. Certain microbes may proliferate in response to age-related changes in the body, while others help drive them, Snyder said. The authors also spotted differences in how diabetic and pre-diabetic people aged as compared to insulin-sensitive people, but it's unclear whether these markers indicate meaningful differences in health status. Many studies suggest that insulin plays a central role in aging throughout the animal kingdom, but more research is needed to clarify its exact influence over human aging.

For now, ageotypes present as many questions as they do answers about human aging. Until scientists understand what various aging markers really mean, clinicians will continue to rely on standard vital sign assessments to track patients' health over time. In the near future, perhaps ageotypes could serve to motivate people to take better care of areas of their body that appear to be aging faster than others, Snyder said. For instance, if someone fits the profile of a cardiovascular ager, they might focus on improving their cardiovascular health and undergoing relevant medical tests to check on their progress.

"As we collect a lot more information, we are going to be better able to follow how people are aging, [as well as] what interventions they did that actually reduced their aging," Snyder said.

Originally published on Live Science.

The rest is here:
Scientists Discover 4 Distinct Patterns of Aging - Livescience.com

Read More...

Artificial Intelligence Expert Neil Sahota Says AI Will Have Major Impact On 2020 Elections And In Medicine – Yahoo Finance

Monday, January 20th, 2020

Sahota Offers AI Predictions for the New Year

LOS ANGELES, Jan. 15, 2020 /PRNewswire/ --Artificial intelligence, or AI, will play a significant role in the 2020 election campaign and may also lead to major breakthroughs in solving personal medical issues, according to futurist and AI expert Neil Sahota.

"I'm increasingly concerned about the impact of fake news, photo scams and other deceits designed to negatively influence voting this year," says Sahota, who works closely with the United Nations and other organizations to foster innovation and develop next generation products/solutions to be powered by AI. "We will see the effect of more AI tools generating fraudulent information and influencing voters. Thankfully, there will also be new tools to fight this kind of disinformation. What is certain is that machine vs machine battles will become more prevalent."

The author of the influential book Own the AI Revolution (McGraw Hill), Sahota is also an IBM Master Inventor, who led the IBM Watson Group and is a professor at the University of California/Irvine.

In addition to its potential impact on the election campaigns, Sahota predicts AI will be responsible for significant medical advances. "We will see more use of AI that will accelerate solutions for doctors, nurses, clinicians and researchers in providing personalized care," he said. "Each of us is genetically unique and there isn't a one-size fits all solution for us. But AI can solve this dilemma by providing personalized medicine based on a specific person's genomic sequence, lifestyle, medical history, environment and other differences. I think there will be great strides in these areas in the coming year."

"The election and medicine are only two areas where we will feel the impact of AI, which is coming into its own as an emerging technology," Sahota says. "We are likely to see it help combine tools such as block chain, virtual reality and artificial reality. For example, I envision a virtual reality courtroom where a law student interacts with an AI 'judge,' opposing counsel and jury. AI simulation is not only more 'real world' but has great variability, meaning each time the VR module is used, it's different. There's no memorization or 'cheat sheet' for the law student. It's a dynamic, highly interactive learning module and 2020 will start the wave of convergence: combining these technologies together.

About Neil Sahota: Neil Sahota is a futurist and leading expert on Artificial Intelligence (AI) and other next generation technologies. He is the author of Own the AI Revolution (McGraw Hill) and works with the United Nations on the AI for Good initiative. Sahota is also an IBM Master Inventor, former leader of the IBM Watson Group and professor at the University of California/Irvine. His work spans multiple industries, including legal services, healthcare, life sciences, retail, travel, transportation, energy, utilities, automotive, telecommunications, media, and government.

View original content:http://www.prnewswire.com/news-releases/artificial-intelligence-expert-neil-sahota-says-ai-will-have-major-impact-on-2020-elections-and-in-medicine-300987177.html

SOURCE Neil Sahota

Originally posted here:
Artificial Intelligence Expert Neil Sahota Says AI Will Have Major Impact On 2020 Elections And In Medicine - Yahoo Finance

Read More...

GSK, Pfizer contradict on the future of consumer health JV report – Endpoints News

Monday, January 20th, 2020

SAN FRANCISCO Few CEOs tell a story better than bluebirds Nick Leschly.

He cuts a Jeff Bezos figure on stage at the Colonial Room, the JP Morgan presentation hall for A-list biotechs: lean and bald, fast-talking and vest-wearing. He explains in simple language, apologizing when he has to brush on the data. It helps that he has a good story to tell.

We treated them one time, Leschly tells a packed crowd, gesturing to the slide behind him. Look what happened.

The slide shows 9 horizontal bars studded with diamonds. Each bar, he explained, represented a sickle cell patient, and each diamond represented a severe medical event, such as a pain crisis. The diamonds stud one side before the therapy and vanish on the other, afterward.

A 99% reduction in these events this is a functional cure for sickle cell disease, Leschly says. This is unprecedented data.

Upstairs and an hour later, Ted Love stands before a narrow conference room in his suit and polka-dot tie. Love, the CEO of Global Blood Therapeutics, is a 60-year-old physician. His voice trails off at the end of sentences, and the story he tells is less compelling. There are no cured patients.

This is the first drug that addresses the root cause of sickle cell disease, Love says, speaking in front of a slide showing a white pill bottle for GBTs new drug Oxbryta. Right in the label, it says that this drug inhibits polymerization.

In the 60 years after scientists discovered the cause of sickle cell, almost no treatments emerged, even as the condition debilitated hundreds of thousands of Americans, most of them black or Hispanic. But the last few years have seen a resurgence of interest as new technologies have made the disease seem newly beatable.

Unlock this story instantly and join 70,000+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

See the original post here:
GSK, Pfizer contradict on the future of consumer health JV report - Endpoints News

Read More...

How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology – DocWire News

Friday, January 10th, 2020

Perthera is a cancer therapeutic intelligence company that leverages Artificial Intelligence (AI) and data-driven therapy recommendations for oncologists to offer precisely tailored treatments to cancer patients based on their genetic factors, molecular profile and much more. The company was founded seven years ago by a team of experts in oncology, biomarkers, bioinformatics, and AI, and has since become a prominent force in bringing precision medicine to oncology. Read on to hear what Gary Gregory, Perthera CEO and President, had to say to DocWire Newsregarding his companys innovative work.

Gary noted that Pertheras primary goal is to harness all the benefits and opportunities of precision medicine in oncology. He added that the patients entire medical and treatment history, as well as their unique, multi-omic molecular profile position, is factored into the Perthera Platform, which is used by the physician to create their customized treatment plan. The patients comprehensive clinical information is run through the companys Therapeutic Intelligence EngineTM, which includes multiple databases, heuristic rules, algorithms and AI, that ultimately delivers a ranked set of therapeutic recommendations that the patients physician can consider. The AI built into the Perthera Platform leverages its computational engine and multiple databases to compile and utilize real-world evidence (RWE) to improve patient outcomes.

We also run each and every patient through our patented, cloud-based, molecular tumor board that allows us to scale a unique and powerful solution, Gary added. This contrasts with most cancer centers where less than 10% of patients typically have the benefit of a molecular tumor board, which has been proven to be highly advantageous from a medical practice perspective.

Another facet of Pertheras mission is to equip pharma, biotech, drug development companies and clinical trial organizations (CROs) with real-world evidence and clinical services that can enable them to expedite drug development, enhance market surveillance of these drugs and accelerate their clinical trials enrollment.

Regarding the advancement of their current technology, Gary noted that the company is always striving to advance Pertheras proprietary algorithms, use of real-world evidence, deployment of AI, and integration of new molecular technologies to continually improve their precision oncology solution.

Were also involved in a number of exciting projects with industry, whether its with pharma companies, CROs or advocacy groups, he added. We partner with them to bring forward their initiatives, the developmental work theyre doing on new therapeutic agents, theyre detailing the clinical efficacy of precision medicine, and even the clinical utility of Pertheras Platform, which has been proven to provide a significant improvement in both overall and progression-free survival.

Pertheras main offering is a Precision Medicine Program for Hospitals and Physicians, which allows healthcare providers to harness and capitalize on the benefits of Pertheras precision oncology platform. This program starts with the physician ordering the Perthera Platform and clinical report. Perthera completely de-burdens the clinical staff by orchestrating all molecular profiling tests, and running the comprehensive clinical information through its Therapeutic Intelligence EngineTM, and then an expert Molecular Tumor Board, consisting of a variety of medical experts, to ultimately produce the ranked therapeutic options.

Next, Perthera delivers a personalized report that is precisely matched to each patient, and contains specific, ranked therapeutic recommendations that are supported by medical, clinical, and scientific evidence, to promote expanded progression-free survival and overall survival outcomes.

The final step in this process involves Pertheras following the patient and capturing comprehensive RWE data regarding the patients treatment and outcomes.

And the physicians and hospitals can use this data for research purposes, whether its for publications, for accelerating their own clinical trials, or simply to advance the care of their patients, Gary explained. The data we collect is made available for their use. We provide it back to them via a dedicated portal so that they can take full advantage of the understanding, analysis and utilization of their specific data, to advance their practice of medicine and care of their patients.

Its also important to note that Perthera now customarily delivers their Platform at low to no charge to hospitals, physicians and patients. This approach has been transformative in allowing many healthcare organizations to capitalize on the Perthera Platform and all it offers to providers and patients.

The computational engine, or Therapeutic Intelligence EngineTM, is at the center of what Perthera offers healthcare providers and patients. This is founded upon their proprietary, comprehensive computational system that Perthera has been building over the course of six plus years.

It features 10 distinct databases and over 50,000 heuristic rules, algorithms and AI, he explained. Every patients data is analyzed by Pertheras Therapeutic Intelligence EngineTM. We provide an initial set of computationally ranked therapies, and then the patients clinical data and information is analyzed and polished by our expert, cloud-based, Molecular Tumor Board which provides the highly unique human in the loop component of our Platform. The byproduct of these elements is the Perthera Report, which has these precisely ranked therapeutic recommendations (including on label, off label and clinical trial options) for the physician to evaluate, choose from and direct their patients medical therapies. As we collect RWE outcomes and treatment selections, we incorporate that data back into our Therapeutic Intelligence Engine, which gains experience over time, to further improve our service and the resulting clinical outcomes.

As previously mentioned, research has shown that if the top-ranked therapies that Perthera suggests are chosen, survival rates are significantly more likely to be improved.

Beginning his work with Perthera in the past year, Gary noted that one of the first things he saw in the company was their proven approach to precision oncology, that was backed by reputable clinical research publications.

Our Platform and service is clinically proven in the sense that its been delivered to over 250 cancer centers and utilized by well over 10% of practicing oncologists across the U.S., he explained. Its also proven through peer-reviewed publications that detail when physicians use the Perthera Platform, they do a better job of harnessing the power of precision medicine and they improve their patient outcomes, both from an overall and progression-free survival.

Its a really exciting clinical arena and marketplace. The care of cancer patients is being transformed before our eyes. As importantly, its an exciting time for Perthera, because we believe were the only company that offers this end to end Platform, that has been proven to advance the care of patients, and also to deliver better clinical outcomes, he concluded. The comprehensive, end-to-end nature of what we do makes Perthera highly unique, and allows us to deliver exceptional value to patients, physicians, hospitals and biopharma companies.

Link:
How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology - DocWire News

Read More...

Evaluating the Pancreatic Cancer Clinical Trial Landscape – Pancreatic Cancer News & Stories

Friday, January 10th, 2020

Editors note: January is Pancreatic Cancer Clinical Trials Awareness Month. Throughout the month, we will feature a Shedding Light on Clinical Trials series that provides key information about clinical trials and how they can benefit pancreatic cancer patients. Todays article gives an overview of the current clinical trial landscape.

There are approximately 170 pancreatic cancer clinical trials currently enrolling patients across the United States. These clinical trials are open at cancer centers, hospitals and community medical practices throughout the country.

The Pancreatic Cancer Action Network (PanCAN) maintains the most comprehensive and up-to-date database of pancreatic cancer clinical trials available in the United States.

Clinical trials are designed to determine whether an experimental treatment or combination is effective, safe and an improvement over the current standard of care options. Participants must meet specific eligibility criteria, which can include their type of pancreatic cancer, the stage of disease, treatment history and other health and wellbeing requirements.

While most clinical trials strive to answer similar questions, the way the trial is designed can vary.

In recent years, theres been an increase in biomarker-driven clinical trials for pancreatic cancer patients.

Biomarkers are biological clues that can be measured from a patients blood, urine, tumor tissue or other specimens. The presence or amount of a biomarker may vary between someone whos healthy and someone with a disease like pancreatic cancer.

Moreover, through a precision medicine approach, biomarkers can provide information about whether a patient is likely to respond to a certain type of treatment.

Some clinical trials are designed to only enroll patients with expression of certain biomarkers, while other trials strive to find biomarkers that could predict a patients response to their experimental treatment.

PanCAN recommends all patients with pancreatic cancer undergo testing to analyze their tumors molecular profile (through testing a sample of tumor tissue) and to determine if they have germline (genetic) alterations that they were born with (through analysis of their blood or saliva).

Both tests are available through PanCANs Know Your Tumor precision medicine service. Patient Central can provide information about Know Your Tumor and other ways to access these tests, as well as provide a list of biomarker-driven clinical trials that may be relevant to the patient.

Another type of trial, adaptive platform trials, allow investigators to ask multiple questions at the same time, rather than testing only one experimental drug against the standard of care.

Adaptive platform trials are designed to learn and evolve over time, with the expectation that additional experimental treatments will be added. If an experimental treatment arm isnt performing well within the trial, it can be discontinued at any time.

Todays pancreatic cancer clinical trials are being designed based on rigorous scientific and clinical evidence and to quickly and efficiently evaluate experimental treatment options to benefit patients.

Pancreatic cancer patients who participate in clinical research have better outcomes. Every treatment available today was approved through a clinical trial. PanCAN strongly recommends clinical trials at diagnosis and during every treatment decision.

View post:
Evaluating the Pancreatic Cancer Clinical Trial Landscape - Pancreatic Cancer News & Stories

Read More...

New year health kicks are great but your environment is also vital – The Guardian

Friday, January 10th, 2020

Exercising and eating better as part of our new year health kicks are great, but we should also think more deeply about the role the environment plays on our health. As a professor of environmental medicine, I believe this is an exciting new area of study that will play a big part in the future of personalized medicine.

Consider this, every day we are bombarded with messages: genes that cause cancer, supplements that prevent Alzheimers disease, diets that prevent asthma, chemicals that make us gain weight. But while headlines frequently proclaim game changing new findings, over the last 20 years in the US and Europe our health status as a population has seriously deteriorated. Rates of obesity, diabetes, heart disease, cancer and learning disorders continue to rise. Genetic variation may be part of the puzzle that explains why we get sick, but clearly there are missing pieces.

After all, 20 years of increasing obesity and diabetes represents only a single generation. If our genes didnt change in the last 20 years, then our environment must have.

Genes never work in isolation. Instead, they determine how we react to our diet, social surroundings, physical environment, infections and chemical exposures. Environment is the missing piece of the puzzle.

The old 20th-century concept of nature v nurture needs to be redefined, as genetics and environment do not compete, they work hand in hand, sometimes to our benefit and sometimes to our detriment. The correct formula is really nature times nurture. Right now the nurture part of that equation is largely unknown, but that may soon change.

Recently, a new concept has arisen, the science of the exposome: the measurement of all the health-relevant environmental factors across the lifetime.

The exposome is to our environment what genomics is to our genetics. Most of what we know about environment and health is still a black box consisting of yet to be discovered risk factors we too often attribute to bad luck ie because we dont measure the environmental cause, the problem appears random.

But most of what we now understand about genetics was also a black box in the 20th century.

Physicians see the role of environment daily even if it is not clear to them that environment is the cause. For example, a child with autism develops more frequent combative oppositional behaviors and emotional outbursts. An adult with diabetes cant seem to control her blood sugar despite higher doses of insulin. A newborn is born with blue skin but a normal heart.

For each of these cases, sequencing the genome would not have identified the cause. The autistic child had lead poisoning because of pica brought on by autism, the diabetic adult used perfumes high in phthalates, chemicals that affect metabolism and the newborn baby drank formula mixed with well water contaminated by fertilizer runoff that reacted with his hemoglobin.

In each case, genomics would not have given us the correct answer, but if we had the tools to measure the exposome, we would have made the correct diagnosis. Just as importantly, because the underlying causes were environmental, we can treat the problem with interventions.

Furthermore, in most diseases, environment and genetics work in combination. Its very rare to have a genetic variant that causes Alzheimers disease, but it is fairly common to have a genetic variant that makes us susceptible to environments that can cause Alzheimers. The different between those with the genetic variant who get sick and those who dont is their different environments.

Imagine a visit to your physician in which you begin by handing over your smartwatch to have its data downloaded, followed by a blood draw to measure your chemical environment and nutritional status, then you update your lifetime home address and occupational history into a secure computer that houses your genomic data. This then computes your personalized risk score for heart disease, diabetes and other diseases. Or, if you already have one of these diseases, computes the ideal treatment regimen based on this big data. This is how we will be able to personalize medicine.

We are not there yet, but the technology to measure the exposome is far more advanced than the general public, and even many researchers, realize. There are now lab tests that can demonstrate the presence of thousands of chemicals in our bodies and satellites that record our daily weather, air pollution, light exposure and built environment. Public records have data on water quality, age of housing, local crime statistics, outdoor noise levels and even where disease clusters are occurring. Cellphones are ubiquitous and can link our daily behavior and movement patterns with the quality of the local air and water while simultaneously measuring our heart rate, physical activity and sleep quality.

Computational science has advanced to a point where storage of terabytes of data is routine and computer clusters are found in every major university and methods to bring these databases together are no longer science fiction. Artificial intelligence and other big data approaches to genomics also provide a roadmap for analyzing exposomic data.

Understanding how environment affects your health will empower people to make the changes in their lifestyle that will matter most. To understand what food to buy, which fragrances to avoid, where and when to exercise, etc. All the pieces to solve this puzzle are beginning to come together. What is needed is the grand vision to invest in and integrate exposomic science into public health and clinical medicine. This is the final piece of the puzzle. Once we understand our exposome and integrate it with our genome, we will finally understand why and how chronic diseases have become so common and how we can start to reverse their trends in society.

Dr Robert Wright is a pediatrician, medical toxicologist, environmental epidemiologist and director of the Institute for Exposomic Research at the Icahn School of Medicine at Mount Sinai

Continue reading here:
New year health kicks are great but your environment is also vital - The Guardian

Read More...

A Few Minutes on the Potential Harm of Predictive Models – Medscape

Friday, January 10th, 2020

Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson.

It's a new year. After a little holiday break, I'm back and, frankly, a bit cranky as I peruse the recently published medical literature. I'm focusing today on a rather small study. It's one that hits a pet peeve of mine, so I'm going to channel my inner Andy Rooney here and gripe for a bit.

Appearing in JAMA Network Open, we have this article with the compelling title "Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients WithDepression."

I like to know what I'm getting into when I read a title, and this title promises quite a bit. To me, it reads like researchers used electroencephalography (EEG) and some fancy machine-learning stuff to predict which patients with depression would benefit from escitalopram treatment.

That ideausing a machine-learning model to choose the best psychiatric treatment is holy graillevel personalized medicine stuff. See, when confronted with major depressive disorder, docs often try medication after medication to see what sticks; anything to lessen that trial-and-error approach would save tons of time, not to mention lives.

But that is not what this study is about. Walk with me through the methods and you'll see what I mean.

Researchers from British Columbia analyzed EEG data from 122 adult patients with major depression who were initiated on escitalopram therapy.

As you know, an EEG outputs a ton of datamultiple electrodes, thousands of measurements. This is actually an ideal place to use machine-learning tools to squeeze all of those data into a single number. The authors do an exemplary job of using a well-established machine-learning algorithm called a support vector machine to take those gobs of data and turn it into a prediction.

But what exactly are they predicting?

They are predicting whether the patient will have remission of depression in 8 weeks. They are not predicting whether escitalopram was good for the patient, and that difference is huge.

This study had no control group; all 122 patients were treated with escitalopram. We therefore have no way to know whether the machine-learning model identified individuals who are more likely to achieve remission regardless of therapy (let's remember that depression spontaneously remits in around 20% of cases) or those who truly benefit from escitalopram.

See, every patient with depression has four potential destinies in regard to escitalopram:

Some will have remission with or without the drug. Some will never have remission regardless of treatment. Some will only experience remission if they get the drug, and others, presumably, would only not experience remission if they get the drug.

It's really the last two categories we care about in terms of deciding on treatment, but ironically, the first two categories are the easiest to predictbecause in the end, the biggest predictor of whether you get remission from depression is not whether you get a drug but how severe your depression is in the first place.

This is a huge difference in terms of a prediction problem and one that can actually lead to patient harm.

Let me give an example.

Imagine that we built a model predicting who is least likely to have a heart attack among a population receiving simvastatin.

Without a comparator group, we'd find that individuals with lower LDL, more physical activity, and no diabetes would have the best outcomes. If we then argue that these are the types of people who should receive statins, we'd be doing a huge disservice to the people with more severe disease at baseline. Our model doesn't tell us who should get the drug; it only tells us who was better off in the first place.

We need models that can target therapies to the right patients regardless of how sick they are at baseline, or else we'll always choose the least sick people to get treatment. Sure, that will make the success rate of therapies look awesome, but it's not how I want to practice medicine.

Okay, back to escitalopram. What this paper shows us is that the authors built a model based on EEG data that show who is likely to have remission of depression. You could argue that the model has nothing to do with escitalopram. The model may predict outcomes equally well among patients on any antidepressant or on no antidepressant at all. In other words, we're no closer to the dream of strapping an EEG on someone's head and knowing what drug to give them than we were before. But studies like this get reported inaccurately all the time, suggesting that we have some new tool in our personalized medicine toolbox.

My biggest fear is that these models get commercialized as some sort of "use this to decide who to treat" black box, which, as we now all understand, is biased against those who are sicker at baseline, even if they would respond well to therapy. The second sentence of the conclusion of this paper reads: "Developed into a proper clinical application, such a pipeline may provide a valuable treatment planning tool."

Not reallynot unless you want to reserve treatment for the least sick individuals.

Could the researchers prove that their model is not simply identifying less severe depression as opposed to escitalopram response? Well, they could show how their model correlates with baseline depression scores or other baseline factors. My bet is that we'd mostly find that the model just identifies those with less severe depression at baseline, but those data are not presented.

And let's remember that although it's very cool to get data about how severe your depression is just from an EEGI mean, that's Star Trek-y and I love itwe have plenty of tools already available to assess depression severity.

So the next time we see a study (using machine learning or otherwise) that claims to "predict response to therapy," the very next question we have to ask is, "How do we know the model isn't simply identifying less severe disease at baseline?"

F. Perry Wilson, MD, MSCE, is an associate professor of medicine and director of Yale's Program of Applied Translational Research. His science communication work can be found in the Huffington Post, on NPR, and here on Medscape. He tweets @methodsmanmd and hosts a repository of his communication work at http://www.methodsman.com.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
A Few Minutes on the Potential Harm of Predictive Models - Medscape

Read More...

Personalized healthcare and better population health? Heres how digital can help achieve that – The European Sting

Friday, January 10th, 2020

(Credit: Unsplash)

This article is brought to you thanks to the collaboration ofThe European Stingwith theWorld Economic Forum.

Author: Paul Hudson, Chief Executive Officer, Sanofi

In November 2019, an Italian surgeon used a virtual reality headset to travel more than 100 kilometres from his location in Rome to an operating room in Terni. His mission? To oversee a laparoscopic procedure being performed in real-time. Thanks to 5Gs low latency, the physician was able to view and zoom in on live images of the patients organs, providing live commentary to the physicians in the operating room. It was a monumental moment for modern medicine, demonstrating the potential of cutting-edge technologies to transform the way we reach and treat patients around the globe.

Innovations like this are becoming more and more common and its clear that technology is going to transform the way that we care for patients around the world from prevention and diagnosis to treatment and beyond. As an industry, were edging closer to personalized medicine and optimized population health, two highly ambitious but important goals. But as we move toward this horizon, we must take care to apply digital innovation strategically across every aspect of our business.

Digital has the potential to fundamentally change the game in R&D and manufacturing, for example:

Relentless R&D engines: I recently visited a lab in Cambridge, Massachusetts, where a robot was operating 24 hours a day, synthesizing 200 proteins at once. It wasnt long ago that a human being would have been tasked with synthesizing all of those proteins, and it would have taken much longer, with more opportunities for error. Scenes like this where technology is embraced and taking over time-consuming, repetitive tasks, freeing human beings to take on more complex, higher-value work are becoming increasingly common in the research and development phase of drug discovery. Scientists around the globe are deploying digitalization to their advantage, and as a result, we are able to understand diseases and reach breakthrough moments faster, which ultimately benefits patients.

Smart manufacturing: Of course, developing treatments faster and more efficiently is just the first step in bringing the right medicines to the patients who need them. Right now, we are at the very beginning of a movement that will improve current manufacturing systems, which often struggle to keep pace with volume and complexity demands. By using leading-edge technology and taking advantage of data to increase efficiencies and improve the agility needed to respond to rapidly changing patient needs, smart factories help to connect the production and distribution processes with R&D. Similarly, the factories are able to quickly change from one manufacturing process to another, greatly limiting the latency time between products and paving the way for the more efficient commercialization of life-saving treatments. These facilities can be up to 160% more productive, increasing factory output by 200% and cutting costs by up to 40%. As equally impressive and important, smart factories are 50% more energy efficient by cutting emissions, reducing pollution and mitigating damage to the environment.

To achieve excellence in both of the areas, the pharma industry must build the foundations necessary for digital to succeed. This includes pursuing company-wide digitalization versus disjointed implementation of the flashiest technologies on the market. To build this foundation, we must ensure that four things happen: firstly, we need to retrain our employees across every division not just in manufacturing or in the lab with the skills they need to work alongside new technologies. In tandem with these efforts, we must also support employees from the factory floor to the C-suite to de-learn old ways of working and embrace a Man + Machine reality.

Thirdly, both of these efforts will require a robust employee engagement movement focused on keeping employees informed of changes and dispelling fears about the Fourth Industrial Revolution. Finally, we need to embrace an industry-wide mindset that celebrates collaboration as the new pathway to innovation. We must have a new open dialogue and partnerships within the innovation environment. If we fail to collaborate and share vital tools such as data, new tools and lessons from start-up pilots, everybody loses. Conversely, if we do all of these things, everyone wins, especially patients.

Of course, these efforts will just scratch the surface of the challenges we face as an industry on our journey to the future of healthcare. But if we focus our energies on equipping our people to succeed and laying the groundwork for digitally enabled companies, digitalization will revolutionize the way we help patients and transform our industry.

Originally posted here:
Personalized healthcare and better population health? Heres how digital can help achieve that - The European Sting

Read More...

EVERSANA and Noom announce strategic partnership to improve therapy adherence and patient engagement for complex therapies – PRNewswire

Friday, January 10th, 2020

The partnership combines EVERSANA's fully integrated patient services model with Noom's digital therapeutic platform. Noom's program is based on cognitive behavior therapy and focuses on increasing patient engagement and improving clinical outcomes by leveraging human coaches and artificial intelligence.

"Despite a long road to diagnosis, adherence to therapy falls to 50% - 80% for patients with complex, chronic diseases who routinely deal with difficulties handling side effects, navigating lifestyle changes, and finding the education and resources needed to understand their disease and care," said Jim Lang, CEO, EVERSANA. "By integrating Noom's proven behavioral health technology with EVERSANA's best-in-class patient service programs, we will help manufacturers give their patients the personalized support they have long needed and deserved."

"This relationship with EVERSANA will enable us to engage with a greater number of Life Sciences partners," said Saeju Jeong, CEO and co-founder of Noom. "While we have helped millions of consumers adopt a healthier lifestyle, Noom is more than just a consumer weight-loss company. We have harnessed the power of psychology to help manage patients with both diabetes and hypertension. As a digital companion to drug therapies, Noom is a powerful agent to drive patient engagement and improve health outcomes at scale."

Pharmaceutical and biotechnology companies worldwide face increasing pricing pressures and the need to demonstrate greater value for their products, often measured by therapy adherence, evidence of the lower cost of long-term care, plus patient engagement and satisfaction. Additionally, the promise of regenerative medicine and precision medicine demands the evolution of traditional patient services to meet the complex needs of smaller patient populations.

Both EVERSANA and Noom are widely regarded for leading the evolution of life science services to serve future market and patient needs. EVERSANA has made significant investments in the development of Patient Services 2.0, a high patient-experience-focused model enabled by technology and analytics. Noom's evidence-based curricula and behavioral psychology program is clinically proven through over a dozen published studies and grants from the National Institutes for Health (NIH).

To learn more about the collaboration, visit eversana.com and noom.com to contact company representatives.

CONTACT: Sarah Zwicky sarah.zwicky@eversana.com +1 (414) 434-4691

David Osborne davido@noom.com +1 (917) 575-9133

About Noom, Inc.

Noom is the world's leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,500 personal coaches, Noom helps people live healthier lives by changing their long-term habits. Millions have benefited from Noom's behavior change courses, including its virtual diabetes prevention program, which was the first of its kind to be recognized by the CDC. The Noom platform is already being used by leading healthcare and pharmaceutical companies to improve treatment outcomes for patients worldwide. The company is headquartered in New York City with offices in Seoul and Tokyo.

About EVERSANA

EVERSANA is the leading independent provider of global services to the life science industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product lifecycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.

SOURCE Eversana; Noom

Home

View original post here:
EVERSANA and Noom announce strategic partnership to improve therapy adherence and patient engagement for complex therapies - PRNewswire

Read More...

Personalized Medicine Market Segment Analysis by Leading Players, Drivers, Regional, Competitive Landscape & Forecast To 2016 2026 – Citi Blog…

Friday, January 10th, 2020

Study on the Personalized Medicine Market

The comprehensive report published by Future Market Insights (FMI) offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Personalized Medicine Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Personalized Medicine Market during the forecast period 2016 2026.

As per the findings of the presented study, the Personalized Medicine Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period 2016 2026. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Personalized Medicine in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.futuremarketinsights.co/reports/sample/REP-GB-1511

The presented study addresses the following queries related to the Personalized Medicine Market:

The presented market report dives deep into understanding the business strategies adopted by leading market players in the global Personalized Medicine Market. Further, the SWOT analysis for leading market players is enclosed in the report along with the revenue share, pricing analysis, and product overview of each company.

The extensive study on the Personalized Medicine Market pinpoints the different factors that are likely to influence the prospects of the Personalized Medicine Market in each region.

Decisive Information Enclosed in the report:

Get Access To TOC Covering 200+ Topics athttps://www.futuremarketinsights.co/toc/REP-GB-1511

Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customized Report As Per Your Requirements athttps://www.futuremarketinsights.co/customization-available/REP-GB-1511

Why Buy from FMI?

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

T (UK): + 44 (0) 20 7692 8790

Read this article:
Personalized Medicine Market Segment Analysis by Leading Players, Drivers, Regional, Competitive Landscape & Forecast To 2016 2026 - Citi Blog...

Read More...

Personalized Medicine Market : Growing Popularity and Emerging Trends in the Market – ReportsPioneer

Friday, January 10th, 2020

Personalized Medicine Market Overview

The Personalized Medicine Market market report provides an in-depth analysis of various market elements that are required for a better understanding of the market. The forecast period mentioned for the study is 2017-2025. Market elements such as market definition, dynamics, research methodology, segments and competitive landscape is used to gauge better market insights. Various factors under the market dynamics section such as drivers, restraints, opportunities and challenges help in adopting various organic as well as inorganic market strategies and approaches. The market estimation for various segments is performed in order to fetch qualitative as well as quantitative insights regarding the market.

Personalized Medicine Market : Market Outlook

Our analysts use various approaches such as primary research and secondary research to fetch the raw data which is further utilized to classify the data on the basis of Top-Down and Bottom-Up Approaches. We also utilize other sources such as industry magazines, government associations, paid databases to validate our data. An executive summary is also provided to our clients helping them to gauge the latest industry trends and forthcoming market insights.

PDF Sample for Current Industry Insights https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=004&utm_campaign=RP

The main objective of the market study is to provide both extrinsic as well intrinsic market insights. The market is broken into smaller segments which helps in building a much more classified market outlook. Each segment is analyzed w.r.t the global market as well as various other micro-markets. Along with the market dynamics, value chain analysis and Porters Five Forces analysis is also provided. Porters Five Forces Model offers insights regarding bargaining power of supplier and consumer along with threats from substitutes and new entrants.

Personalized Medicine Market : Competitive Landscape

The market analysis also encompasses competitive insights for the major industry players and start up ecosystems. In order to fetch insights regarding the positioning of the key industry players, a company ranking analysis is provided. The companies are considered on the basis of following parameters:

Key Player Profiled in the Report Includes Abbott Laboratories, Merck & Co., Inc., AstraZeneca, Pfizer, Inc., GlaxoSmithKline PLC., Novartis AG, Amgen, Inc., Bayer AG, Mylan N.V. and Eli Lilly

Request Discount on the Report https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=004&utm_campaign=RP

About Us-

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. Our large database includes the latest Content from renowned authors and publications worldwide. Weve recently developed one of its own kind smart-system, which helps us determine the authenticity and reputation of the content and its author. This smart-system ensures that we always include high quality content in our database. We also provide customized Data and Reports according to the need of our client. We strive for excellence and perfection in all our work, and our in-house team is working 24/7 so that you get the Data, Reports, and Analytics you need to help make better decisions. We believe in Customer Satisfaction, and to achieve that we aim to understand the clients need to provide tailor-made services.

Our aim is to save your Time and Resources, providing you with the required Research Data, so you can only concentrate on Progress and Growth. Our Data includes research from various industries, along with all necessary statistics like Market Trends, or Forecasts from reliable sources.

Contact Us-

New Jersey ( USA )218 Washington Street,Boonton 07005Tel:+1 (800) 782 1768[emailprotected]

The rest is here:
Personalized Medicine Market : Growing Popularity and Emerging Trends in the Market - ReportsPioneer

Read More...

What to Know in Washington: House to Hold Symbolic Vote on Iran – Bloomberg Government

Friday, January 10th, 2020

The House will vote today on a resolution to limit President Donald Trumps options for military action against Iran, with Democrats unsatisfied by the administrations justification for last weeks airstrike that killed a top Iranian official.

The war powers resolution from Rep. Elissa Slotkin (D-Mich.), a former CIA analyst, would require the president to cease military actions against Iran unless authorized by Congress or in response to an imminent threat. A similar measure in the Senate has been introduced by Sen. Tim Kaine (D-Va.).

The vote is mostly symbolic because the Senate version is unlikely to attract much support from the chambers Republican majority and the House resolution by design would never go to the president to become law.

Speaker Nancy Pelosi (D-Calif.) said it is Congresss duty to keep the American people safe, and she said Trumps actions in the region have endangered diplomats and members of the military by escalating tensions with Iran. Pelosi said the Democratic-led House may also soon consider legislation pushed by the partys progressives to cut off funding for action against Iran and repeal existing military authorizations.

Read the BGOV Bill Summary on the House resolution to end hostilities with Iran.

While the Senate resolution has little chance of passing the Republican-led chamber, Kaine did pick up two GOP supporters yesterday: Sens. Rand Paul (R-Ky.) and Mike Lee (R-Utah) say they will support the resolution. Lee said that Trump administration officials left a briefing for lawmakers on Iran after only 75 minutes, adding hed sought more details on the U.S. drone strike on General Qassem Soleimani but White House officials werent forthcoming. Read more from Erik Wasson and Billy House.

Trumps Soleimani Hit Pays Off: Trump took the biggest risk of his presidency by killing a top Iranian general, and for the moment the bet is paying off. The question now is: For how long? A retaliatory Iranian missile attack on two U.S. bases in Iraq early yesterday caused no casualties, allowing the president an opportunity to stand down from what looked like an escalation toward war. We must all work together toward making a deal with Iran that makes the world a safer and more peaceful place, Trump said in remarks to the nation.

The Jan. 2 strike that killed Soleimani was a dramatic show of strength that, at least for now, reset the power dynamic between the U.S. and Iran. Trump appears to believe Iran will now think twice about provoking the U.S. and the two nations could even begin to forge a new understanding to reshape fraught Middle East politics. But its not at all clear that Iran is done with its reprisals. Read more from Justin Sink.

Trump yesterday vowed more sanctions as part of his maximum pressure campaign against Iran. The penalties are likely to target key regime figures and the countrys metals sector, a person familiar with U.S. plans said. The sanctions will likely be aimed at non-oil sectors of the Iranian economy and fit into a previously disclosed administration plan to choke off other sources of revenue now that the U.S. has clamped down on the nations oil exports, said the person, Nick Wadhams reports.

House to Vote on PFAS Bill Thats DOA in Senate: A far-reaching House bill that would force the federal government to address per- and polyfluoroalkyl substances, or PFAS, contamination has little hope of becoming law in its current form, according to the chairman of the Senates environment committee. It has no prospects in the Senate, Sen. John Barrasso (R-Wyo.) said in an interview. None.

Barrassos comments came as the House is swiftly moving toward passage of the bill, which would change the way these persistent and potentially toxic chemicals are regulated. In addition to forcing the EPA to set nationwide drinking water standards for the chemicals, the bill also would require the agency to add the chemicals to its hazardous substance list, which potentially could turn every contaminated location into a Superfund site. Read more from David Schultz.

For more on the PFAS bill, see the BGOV Amendments Summary and BGOV Bill Summary by Adam M. Taylor.

Some Democrats Ask Pelosi to Let Trial Begin: Pelosi will hold her weekly news conference today amid the standoff over sending the impeachment charges against Trump to the Senate. Several Democratic senators are pressuring Pelosi to transmit the impeachment articles and let the Senate trial begin, and one said the trial could start next week.

If were going to do it, she should send them over. I dont see what good delay does, said Sen. Dianne Feinstein (D-Calif.).

Pelosi said she is holding back the articles of impeachment adopted by the House last month until Senate Majority Leader Mitch McConnell (R-Ky.) sets out his rules for the trial. But Sen. Chris Murphy (D-Conn.) suggested the House has little leverage in the matter. My expectation is that well be able to start this trial next week, Murphy said. The leverage over Republicans exists in the votes we take inside the trial. Read more from Billy House and Laura Litvan.

Sekulow to Join Trump Defense Team: Attorney Jay Sekulow will be a member of Trumps defense team for the Senate trial, according to a person familiar with the matter. Sekulow, who became one of Trumps private lawyers in mid-2017, specialized in constitutional issues in the Mueller investigation. White House Counsel Pat Cipollone will lead Trumps legal team for the trial. Separately, Rep. Jim Jordan (R-Ohio) is being recommended by some of the presidents allies to the White House as a possible member of his defense team. Read more from Jordan Fabian and Billy House.

Democrats Unveil Plan for 100% Clean Energy: House Democrats yesterday released ideas for future bills aimed at getting the U.S. to 100% clean energy by 2050 and said theyd work to build support for it in the months ahead. House Energy and Commerce Chairman Frank Pallone (D-N.J.) called the ideas a framework for a measure that will be called the Climate Leadership and Environmental Action for Our Nations Future, or CLEAN Act. The bill hasnt been introduced, and Pallone said draft text would be released around the end of the month. Read more from Dean Scott.

IRS Asked to Advise Nonprofits on Refunds: The IRS should issue guidance instructing tax-exempt organizations how they can claim refunds for overpaid taxes after Congress repealed a portion of the 2017 tax law, House Ways and Means Chairman Richard Neal (D-Mass.) and Rep. John Lewis (D-Ga.) wrote in a letter to the agency. The 2017 tax overhaul required nonprofits to pay a 21% tax on parking and transportation benefits that they offer to employees, but lawmakers repealed the provision in December. Read more from Laura Davison.

FCC Pirate Radio Fines: The Senate unanimously cleared legislation that would allow the Federal Communications Commission to impose up to $2 million in fines against unauthorized radio broadcasters, or so-called pirate radio stations. The bill from Rep. Paul Tonko (D-N.Y.), now heads to the presidents desk. The House passed the bill last February. Read more from Jon Reid.

Trumps Iran Strike Delights Supporters: Trumps loyal political base is standing by his decision to kill a top Iranian general, polls show, even though the move may undermine a key 2016 pledge to end U.S. military involvement in the Middle East. And recent polls show a clean partisan divide on the confrontation. About 67% of Republicans said they either strongly or somewhat approve of Trumps handling of Iran in the days following the U.S. airstrike on Soleimani, according to a Reuters/Ipsos poll released Tuesday. About 69% of Democrats strongly disapprove.

But the political impact of the strike may be most telling among independent voters. About 48% of independents had a negative response to the presidents handling of Iran while roughly 36% answered positively, according to Reuters/Ipsos. And overall, a majority of Americans 53% disapproved of Trumps handling of Iran following the strike, an increase of 9 percentage points from December. Read more from Mario Parker.

Buttigieg Ad Highlights Black Support: Pete Buttigieg is seeking to overcome low support from black voters in South Carolina with a new ad highlighting residents of South Bend, Ind. The 30-second spot avoids any direct mention of race, but it features four black residents praising Buttigiegs record in the city. He listened to our community, says one resident. In recent weeks, Buttigieg has stepped up efforts to win over black voters, who make up the majority of Democrats in South Carolina, meeting with African-American leaders and holding smaller events. Read more from Ryan Teague Beckwith.

DOJ Says Virginias Push for Equal Rights Amendment Futile: The Virginia General Assemblys new Democratic leadership has opened the legislatures session with a pledge to adopt the Equal Rights Amendment. But a U.S. Justice Department official says in a newly released legal opinion that those efforts are in vain, as a 1979 ratification deadline set by the U.S. Congress has passed.

The ERA resolution has expired and is no longer pending before the States, according to Steven A. Engel, assistant attorney general with the Office of Legal Council. That deadline is binding and Congress has to restart the process, Engel said in the memo. Engels legal guidance was issued as Virginia appears to be poised to ratify the amendment. The commonwealth would become the 38th state to approve the ERA, which aims to set a broad guarantee of equal rights under the law, regardless of sex. Read more from Andrew M. Ballard.

Facebook Will Give Users the Option to See Fewer Political Ads: Responding to popular demand, Facebook will soon give users the option to see fewer political and social issue advertisements in their feed. This new setting, which will also be available in Instagram, is part of an effort to give people more control over what they see ahead of the 2020 U.S. presidential election.

Facebook announced the new option Thursday in a broader update about political ads on the service. The company did not, however, announce major changes or restrictions to the ad-targeting tools available to political campaigns. Facebook has discussed potential changes to ad targeting internally in recent months following restrictions from rivals Google and Twitter Inc. The social network decided against changing its targeting tools, which can be very granular and specific, after extensive outreach and consultations with third parties, the company said in a blog post.

Facebook is also sticking with a controversial policy that stipulates the company will not fact-check posts from politicians, including political ads. Read more from Kurt Wagner.

(Michael Bloomberg is also seeking the Democratic presidential nomination. Bloomberg is the majority owner of Bloomberg Governments parent company.)

Kuwaiti Cash Fuels Misleading U.S. Media Coverage: A business executive accused of financial crimes in Kuwait is getting support from an all-star cast of famous Americans, including a son of the U.S. president who liberated the Gulf nation and several of Trumps allies. Theyve helped generate a torrent of sympathetic media coverage from the Middle East to Washington. The boldface names are part of a $4.9 million campaign that also has been marked by subterfuge and deception, including a fake protest, thousands of dollars in payments to some U.S. opinion writers, misleading news reports and a correspondent who may not exist. A review of government filings and an examination of dozens of articles shows just how easily money can warp U.S. press coverage. Read more from Zachary R. Mider, Benjamin Elgin and Joe Light.

Chinas Liu He to Travel to U.S. for Trade Deal Signing: China announced that Vice Premier Liu He will travel to Washington to sign the first phase of the trade deal with the U.S. next week, locking in Beijings commitment to a ceremony already announced by Trump. Liu, who has acted as Chinese President Xi Jinpings top trade negotiator throughout the tariff conflict, will travel to the U.S. from Jan. 13 to Jan. 15 at the head of the delegation, Ministry of Commerce spokesman Gao Feng said today in Beijing. He said he has no more information to release about the trade talks, other than that the teams remain in close contact. Read more.

Medical Testing Sector Awaits Court Clarity on Patents: Medical companies that develop tests to diagnose neurological disorders, heart disease risk and fetal abnormalities have been in legal limbo since a 2012 Supreme Court ruling that limited the patenting of such tests, finding they occurred in nature and were not invented. The high court may signal as soon as tomorrow whether it will revisit the subject as such tests become critical to the burgeoning field of personalized medicine, in which doctors determine whether a patient is genetically susceptible to a particular disease or would respond to certain treatments. Read more from Susan Decker.

The Cost of IRSs Failure to Collect From Tax Cheats: The average U.S. household is paying an annual surtax of more than $3,000 to subsidize taxpayers who arent paying all they owe, a new report from the Taxpayer Advocate Service found. Reduced funding for the Internal Revenue Service has led to lower staffing levels and fewer audits, which has reduced the amount the IRS has been able to collect from taxpayers voluntarily or through enforcement, the Taxpayer Advocate, an independent branch of the IRS, said in its annual report to Congress yesterday. Read more from Laura Davison.

Private Push for Trump Wall Hits Legal Snags: An effort to build pieces of Trumps Mexico border wall using private funding and land has run into an unlikely obstacle the federal government. The U.S. International Boundary and Water Commission isnt exactly a core pillar of the Trump administration. But with help from the top federal prosecutor in southern Texas, the agency is pushing back against the likes of Steve Bannon and other Trump allies who are trying to put up an 18-foot tall bollard-style barrier along a 3 1/2-mile stretch of the Rio Grande that they claim is used for illegal border crossings and drug smuggling. Read more from Peter Blumberg and Tom Korosec.

To contact the reporters on this story: Zachary Sherwood in Washington at zsherwood@bgov.com; Brandon Lee in Washington at blee@bgov.com

To contact the editors responsible for this story: Giuseppe Macri at gmacri@bgov.com; Loren Duggan at lduggan@bgov.com

Continued here:
What to Know in Washington: House to Hold Symbolic Vote on Iran - Bloomberg Government

Read More...

Disruptive Technologies in Pharma 2020 – the "Healthcare Disruptors" – – pharmaphorum

Friday, January 10th, 2020

SMi has released an exclusive interview with industry expert Shikta Das, Independent Senior Data Scientist, ahead of the upcoming Disruptive Technologies in Pharma conference this January.

Disruptive Technologies in Pharma will bring together experts in pharma technology to explore the latest developments within artificial intelligence, machine learning, IoT, digital therapeutics, eHealth and blockchain, highlighting the challenges of implementation and how to overcome them.

During the run-up to the conference, SMi interviewed industry expert and conference speaker Shikta Das, an Independent Senior Data Scientist. Here is a snapshot of what was discussed:

What is your background in disruptive technologies and which technologies have you been involved with throughout your career?I have been a research scientist most of my career and recently started working with the pharma industry as a Data Scientist. My undergraduate degree was in Zoology and I became fascinated with the advances in genomics with the human genome coding in 2001. Therefore, I decided to study for an MSc in Bioinformatics from Birkbeck, London. That MSc opened the door to Imperial College Londons Bioinformatics team, working with pioneering bioinformatics research. I loved Imperials open mindedness and focus on innovation and decided to purse my PhD there. I thoroughly enjoyed that rigour and became a well acknowledged PhD. To be honest, I have never looked back since then.

I had long been at the edges of Data Science I have been handling large amounts of data and running statistical modelling on clinical datasets, both of which seemed fundamental requirements for data science nowadays. I have continued to gain good coding experience in R since my MSc days and a great passion for personalized medicine- it is no accident that I have ended up in pharma! Also as I was very keen on learning prediction from data, I got involved with ML.

As a data analyst in healthcare, what is your insight on the digital transformation process of the healthcare sector and the need for such transitioning?In my work, I spend a lot of time thinking about qualitative and quantitative data and connecting digital technologies with predictive models

To read the full interview, visit: http://www.disruptivetech-pharma.com/pr8

Shikta Das will be presenting on Healthcare Disruptors, which will cover recent advances in using AI in Healthcare and the impact of AI in Healthcare.

Disruptive Technologies in Pharma20th 21st January 2020London, UK

ENDS Contact Information:For media enquiries contact Neill Howard on +44 (0)20 7827 6164

View post:
Disruptive Technologies in Pharma 2020 - the "Healthcare Disruptors" - - pharmaphorum

Read More...

Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia – A Free Webinar from the Brain & Behavior Research Foundation -…

Friday, January 10th, 2020

New York, Jan. 08, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia on Tuesday, January 14, 2020, from 2pm to 3pm ET. Gregory A. Light, Ph.D., University of California, San Diego, will be the presenter.

Dr. Light will describe precision medicine trials his team has conducted which significantly reduced symptoms and improved cognitive and daily functioning in patients with chronic psychosis in a real-world setting: a long-term community inpatient facility. They also found that reliable, easy-to-obtain signatures of brain-wave activity recorded at the outset of treatment can be used to identify which patients are most likely to benefit (or not) from treatments. This work ultimately aims to develop personalized biomarker assessment tools to deliver the right treatment to the right person at the right time, to improve outcomes among the millions of people with psychotic disorders, most notably schizophrenia.Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation and Host and Executive Producer of the public television series Healthy Minds, will be the moderator. Join by phone or on the web at bbrf.org/januarywebinar.

This webinar is part of a series of free monthly Meet the Scientist webinars on the latest developments in psychiatry offered by the Brain & Behavior Research Foundation.

The Brain & Behavior Research Foundation The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia, as well as research on suicide prevention. Since 1987, the Foundation has awarded more than $408 million to fund more than 4,800 leading scientists around the world, which has led to over $4 billion in additional funding. 100% of every dollar donated for research is invested in research grants. BBRF operating expenses are covered by separate foundation grants. BBRF is the producer of the Emmy nominated public television series Healthy Minds with Dr. Jeffrey Borenstein, which aims to remove the stigma of mental illness and demonstrate that with help, there is hope.

Go here to read the rest:
Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia - A Free Webinar from the Brain & Behavior Research Foundation -...

Read More...

Page 29«..1020..28293031..40..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick